Suvoda Exceeds 2021 Targets; Poised for Continued Growth Supporting Complex Clinical Trials in 2022
PR94176
PHILADELPHIA, Jan. 24, 2022 /PRNewswire=KYODO JBN/ --
-- Surpasses 900 trials across 65 countries, expands leadership team and
product offerings, and posts another year of 30% growth, all while maintaining
an exceptional performance level.
Suvoda, LLC (
) , a global clinical trial technology company that specializes in highly
complex studies, such as oncology, central nervous system (CNS) and rare
disease, today announced that 2021 was another record year, exceeding its
bookings targets and expanding its reach by supporting complex clinical trials
in 65 countries. As clinical trial sponsors and CROs have had to adapt to
pandemic realities, offering hybrid or even fully remote trials, Suvoda quickly
accelerated its roadmap plans to build on its IRT flagship solution (
), offering an integrated eConsent solution, now in the early adopter phase,
and with plans to offer an integrated eCOA solution in 2022.
Logo - https://mma.prnewswire.com/media/1039295/Suvoda_Logo.jpg
"2021 saw tremendous advancements in the clinical trial space, while also
putting unprecedented pressure on those who manage them, especially those
trials that bring life-sustaining treatments to patients around the world,"
said Jagath Wanninayake, CEO of Suvoda. "The ability to handle these
complexities is inherent in our products and services. We are proud that we
have been able to alleviate some of that burden for our customers and look
forward to expanding that support through our unified products as trial
sponsors and CROs look for solutions to the challenges of today's trials."
Rapid, Controlled Expansion
In 2021, Suvoda added 170 employees worldwide, including making two
significant, strategic additions to its executive leadership team. E.K. Koh
joined as Chief Product Officer and Elena Filimonova as Chief Marketing
Officer. Both were selected for their deep experience in scaling global B2B
tech organizations. Following the appointment in 2020 of Yuko Fukasaku as
Suvoda Japan President, the company officially opened its Tokyo office in 2021
and, in the same year, saw its first Asian-based trial using Suvoda IRT go live
for a Japanese sponsor.
Focus Fuels Success
Suvoda reported 30% growth in bookings compared to 2020 and is on track to
surpass 1,000 trials by the end of this quarter. According to the Tufts Center
for the Study of Drug Development, the number of investigational products
targeting cancer has nearly quadrupled since 2000. Complexity is also on the
rise. In fact, the level of complexity in oncology, CNS and rare disease trials
is increasing dramatically due to myriad factors, including a move to hybrid
trials. Suvoda attributes its success to its laser focus on complex trials, its
superior level of customer service and support, and its well-prepared people.
Despite the incredible pace of change and growth, Suvoda has remained committed
to its values and rigorously-defined processes, and as such, the company has
continued to:
-- maintain a customer satisfaction score of 9 out of 10;
-- meet 100% on time delivery for customer acceptance;
-- deliver the cleanest IRT system in the industry with 0.5 average UAT
defects; and
-- complete implementations for complex trials within four to six weeks.
"Change is inevitable, which is why we design our services and support teams to
bring expertise and consistency to each and every complex clinical trial," said
Rob Hummel, chief operating officer of Suvoda. "As we move into 2022, we are
looking forward to continuing to bring steady, measured, yet urgent support to
our sponsors, CROs and partners so they have the data they need, no matter the
patient location, to make informed decisions fast."
-Tufts Center for the Study of Drug Development, Impact Report, Analysis and
Insight Into Critical Drug Development Issues, Volume 23, Number 3, May/June
2021
About Suvoda
Suvoda is a global clinical trial technology company that specializes in highly
complex, life-sustaining studies in therapeutic areas like oncology, central
nervous system (CNS), and rare disease. Founded in 2013 by experts in eClinical
technologies, Suvoda empowers clinical trial professionals to manage the most
urgent moments in the most urgent trials through advanced software solutions
delivered on a single platform. Headquartered outside Philadelphia, Suvoda also
maintains offices in Portland, OR, Barcelona, Spain, Bucharest, Romania and
Tokyo, Japan. The company consistently boasts customer satisfaction scores of 9
out of 10 and has been selected by trial sponsors and CROs to support more than
1000 trials across 65 countries. To learn more, visit www.suvoda.com. Follow
Suvoda on Twitter (
) and LinkedIn (
).
SOURCE Suvoda LLC
CONTACT: Deb Massa, Suvoda, dmassa@suvoda.com, 610.241.2170
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。